Actovegin

DRUG2 trials

Sponsors

Takeda

Conditions

Peripheral Arterial DiseasesPost-Stroke Cognitive Impairment (PSCI)

Phase 3

Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)

CompletedNCT01582854

TakedaPost-Stroke Cognitive Impairment (PSCI)

Start: 2012-06-30End: 2014-11-30Updated: 2016-02-22

Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB

CompletedNCT03469349

TakedaPeripheral Arterial Diseases

Start: 2018-05-01End: 2019-08-28Updated: 2020-10-28

Related Papers

ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin)

Stroke2017-04-2186 citations